Congress buried organ transplant fees and a Middle East FDA office in pediatric cancer bill
H.R. 1262 — Give Kids a Chance Act of 2025 · Filed by Michael McCaul (R-TX) · 313 cosponsors · Introduced Feb 12, 2025 · Passed chamber
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends federal drug approval rules to require pharmaceutical companies developing cancer treatments for children to conduct pediatric studies and submit assessments before approval. It clarifies enforcement procedures, extends priority review vouchers for rare pediatric diseases through 2029, tightens orphan drug exclusivity rules to allow competing treatments for the same indication, and establishes an FDA office in Abraham Accords countries to harmonize drug manufacturing standards. It also creates a registration fee system for organ transplant networks and increases transparency in generic drug applications.
Why we flagged it
The core mechanism mandates pediatric cancer studies and clarifies FDA enforcement, but the bill also bundles orphan drug exclusivity changes, organ transplant fees, and a new international FDA office—making it a multi-purpose regulatory package rather than a focused pediatric cancer bill.
- Section 8 adds a new fee collection authority for organ transplant networks, unrelated to pediatric cancer drug development or the bill's stated purpose.
- Section 9 establishes a new FDA office in Abraham Accords countries for regulatory harmonization—a geopolitical/trade initiative substantively unrelated to pediatric cancer studies.
3 unrelated provisions were flagged in total.
What the text implies
- Orphan drug exclusivity narrowing (Section 6) may reduce financial incentives for rare disease drug development by allowing competing treatments for the same indication sooner, potentially slowing innovation in rare pediatric cancers despite the bill's stated pediatric focus.
- Organ transplant registration fees (Section 8) create a new revenue stream for HHS but shift operational costs to transplant networks; the fee structure and distribution mechanism are opaque and subject to future appropriations, creating uncertainty for transplant centers.
The full analysis lists 5 implications of this text.
Who stands to gain
Pharmaceutical companies developing pediatric cancer drugs (via extended priority review vouchers an; Generic drug manufacturers (via increased transparency on brand-name drug formulations); Organ procurement organizations and transplant centers (via registration fee collection authority, t